



Worldwide First Clinical Application of Dolphin® Transmission Detector

Radiation Therapy Clinic in Bayreuth has clinically implemented Dolphin® which ensures higher quality cancer therapy and a more efficient patient Quality Assurance (QA) process.

Schwarzenbruck, August 16, 2016 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy quality assurance for the treatment of cancer, announces the **first worldwide clinical implementation** of its newly released **Dolphin** Online Ready Patient QA and Monitoring. The team at the Radiation Therapy department of the Klinikum Bayreuth GmbH in Germany, has successfully validated and clinically implemented three Dolphin systems at two of their sites.

This milestone allows the clinic to set a trend in terms of radiation therapy treatment quality. Compared to conventional QA solutions, Dolphin provides a significantly higher treatment dose measurement resolution and capability to detect and verify possible dose discrepancies. Patient QA workflow efficiency is increased with Dolphin's "plug and play" wireless design and instant setup.

"We are proud to provide the highest level of treatment quality and safety to all our patients. Prior to each patient treatment, an intensive quality assurance is performed with Dolphin. This is our basis to achieve the highest QA standards today and in the future," said **Mathias Dierl**, head of Medical Physics at the Klinikum Bayreuth.




Mathias Dierl (second from right), Head of Medical Physics with his team:
"With Dolphin we are able to provide a measurement-based quality assurance for all our IMRT patients, and therefore can guarantee safe treatments."

The Dolphin dose measurements are analyzed with a sophisticated TPS-Class verification software package; the instant verification functionality provides **automatic analysis** and displays an "OK" message for the tests that have successfully passed. The clinical relevance of the patient dose



discrepancies can be comprehensively determined in **3D patient anatomy with DVH** and Oran-at-Risk pass/fail analysis.



At the clinic in Bayreuth, highly complex IMRT treatment plans are delivered and measured with Dolphin prior to each patient treatment. The sophisticated TPS-Class software allows verification of dose deviations in 3D between the plan and delivered, as well as Dolphin-measured actual dose in the patient's anatomy.

“Treatment quality and patient safety comes first in our clinic. Therefore we are pleased to use the most advanced solution Dolphin for all our intensity modulated cases,” said Head of the clinic **Prof. Dr. Ludwig Keilholz**, together with his colleague **Dr. Jochen Willner**, Dept. of Radiation Oncology, Klinikum Bayreuth.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1300 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com.

Media Contact:

Priscilla Alvarez Ulate
 Marketing Communication Specialist
 IBA Dosimetry
 Priscilla.Alvarez-Ulate@iba-dosimetry.com
<http://www.iba-dosimetry.com/>

Press release |